COMMUNIQUÉS West-GlobeNewswire

Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year
24/08/2026
Company Achieves Record Growth Through Peak Rainy Season, with Management Confirming Even Greater Output Within Reach ANN ARBOR, Mich., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
Felix Health launches sleep apnea care through new collaboration with MedSleep
24/08/2026
With more than one in four Canadian adults estimated to be at high risk for obstructive sleep apnea, Felix is expanding into sleep apnea care to help patients more easily access assessment and appropriate treatment. The [...]
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
24/08/2026
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with [...]
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
24/08/2026
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
24/08/2026
Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter [...]
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
24/08/2026
Company intends to accelerate the rehabilitation of Canndoc’s flagship Nir Oz facility, supporting a return to full production and the Company’s expansion in the growing German medical cannabis market NEW YORK and [...]
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
24/08/2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Mesoblast Financial Results and Corporate Update Webcast
24/08/2026
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
24/08/2026
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED [...]
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
24/08/2026
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) [...]
WONDERLAB and United Family Healthcare | Global Health Summit 2026
24/08/2026
HONG KONG, Aug. 24, 2026 (GLOBE NEWSWIRE) -- The partnership will advance microbiome research in metabolic health, while WONDERLAB showcases SHAPE100™ research and its AKKKING™ metabolic-health formula. WONDERLAB has [...]
A Race Against Blindness Launches New Yukon Denali + Serenova Trailer Fundraiser to Help Cure Childhood Blindness
24/08/2026
One of the nonprofit’s most-loved campaigns returns with an upgraded 2026 GMC Yukon Denali, Grand Design Serenova travel trailer, and $50,000 cash—all supporting research for inherited retinal diseases GILBERT, Ariz. , [...]
NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS
24/08/2026
Poster presentation at the ALS Association’s ALS Nexus conference, August 23-26 Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action Data showed that NRG5051 displays [...]
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
24/08/2026
The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME [...]
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
24/08/2026
The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME [...]
TME Pharma provides update on its activities
24/08/2026
TME Pharma provides update on its activities TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement. Discussions and potential partnership are aimed at [...]
TME Pharma fait le point sur ses activités
24/08/2026
TME Pharma fait le point sur ses activités TME Pharma entre dans la phase finale d’évaluation de négociations avancées avec deux partenaires potentiels en vue d’un accord de licence. Ces négociations et ce partenariat [...]
New EON hearing aid portfolio strengthens Phonak’s leadership in speech understanding, scene intelligence and Made-For-All connectivity
24/08/2026
STÄFA, Switzerland, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Phonak today launched EON, its next-generation hearing aid platform. Powered by the newly developed HYPERSONIC™ chip, EON combines Spheric Speech Clarity 3.0, [...]
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
23/08/2026
Company to host a conference call to discuss the ORM-1153 IND clearance and provide a high-level overview of the Phase 1 clinical study BOSTON and DAEJEON, South Korea, Aug. 22, 2026 (GLOBE NEWSWIRE) -- Orum [...]

Pages